The proliferative response of murine lymphocytes to interleukin-2 (IL-2) was examined under physico-chemical conditions present in solid tumours, namely low oxygen and glucose concentrations and acidic pH. Lymphocytes were cultured for four days in 30Uml-' IL-2 to simulate serum IL-2 concentrations attainable with high-dose systemic IL-2 therapy. Lymphocyte proliferation was significantly (P<0.05) reduced by low oxygen concentrations (both anoxia [0%02] and hypoxia [10%, low glucose (6mgdl-1), or acidic pH (6.7 or 6.4). Moderate glucose concentration (32mgdlP'), or neutral pH (7.0) did not impair proliferation. This study indicates that impairment of lymphocyte proliferation by tumour physico-chemical conditions may be a factor in the relatively poor success rate of IL-2/LAK cell immunotherapy.
Interleukin-2 (IL-2) provides a second signal for proliferation and differentiation of activated T lymphocytes (Ruscetti & Gallo, 1981; Bubenick, 1990) . Clinical trials with lymphokine-activated killer (LAK) cells and IL-2 have been disappointing, with clinical response observed in only a few tumour systems, notably malignant melanoma and renal cell carcinoma. Even with these tumours, complete remissions have occurred in only 10-20% of patients (Rosenberg et al., , 1987 . The disparity between in vitro and in vivo results may be due in part to poor localisation of LAK cells to solid tumours (Lotze et al., 1980) . Tumour remissions have been reported with systemic IL-2 treatment alone (Lotze et al., 1986; Louie et al., 1989; Oliver et al., 1989; Sosman et al., 1990) . The anti-tumour effects of IL-2 are believed to be due to activation and proliferation of tumour-infiltrating lymphocytes (TIL) (Ettinghausen et al., 1985; Eggermont et al., 1987) , although lymphocytes activated by IL-2 at distant sites may traffic to tumours as well. The tumour microenvironment differs markedly from that within non-neoplastic tissues, due primarily to insufficient vascular supply and decreased tumour blood flow (Vaupel et al., 1989) . Among the physico-chemical conditions which comprise the tumour microenvironment are low oxygen and glucose concentrations, as well as acidic pH due to insufficient removal of lactic acid (Gullino et al., 1964; Vaupel et al., 1981) . As the distribution of nutrients and pH is frequently heterogeneous within tumours (Vaupel et al., 1981 (Vaupel et al., , 1989 , TIL may be exposed to a range of physico-chemical conditions depending upon their location. TIL are generally observed in the tumour periphery and stroma, but may also be more centrally located in direct contact with neoplastic cells (Dvorak et al., 1981; Bhan & DesMarais, 1983; Vaage & Pepin, 1985) . The purpose of the present study was to determine whether the range of physico-chemical conditions reported in solid tumours could influence IL-2-stimulated proliferation of TIL.
Materials and methods

Mice
Male and female BALB/c mice from 2-6 months of age were used in these experiments. The mice were originally obtained from the Cancer Research Laboratory, University of California at Berkeley, and were maintained in our animal facility by brother-sister mating.
In vitro tymphocyte proliferation Mice were sacrificed by cervical dislocation, and their spleens were dispersed by pushing through a 40 mesh wire screen. The cells were allowed to adhere for 45min on 100mm tissue culture dishes. Nonadherent cells were collected and erythrocytes were lysed with NH4Cl (0.14M in Tris base), followed by two washes with Hanks' balanced salt solution (HBSS, Gibco Laboratories, Grand Island, NY) . Lymphocytes were resuspended to 106 live cellsml1' in appropriate media (see below) together with 30 U ml-1 of recombinant human IL-2 (Cetus Corporation, Richmond, CA) and 4 x 10-5M 2-mercaptoethanol (2-ME). The specific activity of this IL-2 preparation was 3 x 106UMml-'. This concentration of IL-2 was chosen because 30 U ml-IL-2 is reported to be achievable in serum during systemic treatment (intravenous infusion over 6h) with IL-2 at 106Um-2 (Mertelsmann & Welte, 1986 microtiter plate, inside a plexi-glass chamber connected via Tygon tubing to a tank containing 95% N2/5% CO2 (anoxia) or 1% 02/94% N2/5% CO2 (hypoxia). The chamber was placed within a 37°C incubator. Oxygen concentrations were measured via an MI-730 Micro-Oxygen electrode (Microelectrodes, Inc., Londonderry, NH) and determined to be 0.2% and 1.3% when cells were gassed with 0% 02 and 1% 02, respectively. Aerobic controls were incubated at 37°C in room air/5% CO2. Lymphocytes were cultured in IL-2 for 72h, then 3H-thymidine (0.5pCi/tube) was added. (Tubes were briefly removed from the hypoxia chamber in order to add the radioisotope). Eighteen h later, cells were harvested with a cell harvester, and 3H-thymidine incorporation into cells was determined with a beta counter. Addition of 3H-thymidine and harvesting of lymphocytes was similar for the other proliferation assays described below.
Low glucose Glucose-free Dulbecco's Minimal Essential Medium (DME, Sigma Chemical Company, St Louis, MO) was supplemented as described above for RPMI-1640, except that pyruvic acid and NCTC-109 were omitted, and the concentration of FCS was reduced to 2%. The glucose concentration in this medium (as measured with the Glucose HK-10 Test Kit from Sigma) was approximately 6mgdl1'. Glucose (alpha-D(+)glucose, Sigma) was added to yield a final concentration of either 32mgdl-' or 125 mgdl-'. IL-2-stimulated lymphocyte proliferation in varying glucose concentrations was evaluated by resuspending lymphocytes to 106ml`' in each of the three media, together with IL-2 and 2-ME as described above. 2 x I05 cells (200 fd)/well were dispensed into 96 well round-bottom microtiter plates. Plates were centrifuged daily and half of the medium was replaced with new medium in order to compensate for utilisation of glucose by the actively proliferating cells.
Acidic pH SRPMI was adjusted to pH 7.4, 7.0, 6.7, or 6.4 by addition of 1 NHC1 or 1 NNaOH, then sterile filtered. Lymphocytes were resuspended in IL-2 and 2-ME and dispensed in microtiter plates as described above. One-half of the medium in each well was replaced each day with fresh IL-2-containing medium (adjusted to proper pH immediately before use) in order to minimise pH variations. Values for pH were found to fluctuate by 0.1-0.2 pH units during the assay.
Statistical analysis Data from typical experiments under each set of physical conditions were chosen for statistical analysis. For assays in which pH or glucose were varied, the one-way analysis of variance (ANOVA) was used to determine whether treatment effects were present for pH or glucose levels. Where ANOVA indicated the presence of significant treatment differences, pairwise differences were evaluated by Tukey's Multiple Range Procedure (Zar, 1984) . For assays of lymphocyte proliferation in varying 02 concentrations, Student's t-test was used to compare pairwise differences.
Results
Lymphocyte proliferation in low oxygen concentrations IL-2-stimulated lymphocyte proliferation under hypoxic (1% 02) and anoxic (0% 02) conditions was compared with proliferation in room air (20% 02)-Proliferation was similar in both 1% 02 and 0% 02, and for both conditions was significantly less than in room air (P<.0001 and P=.0049, respectively) Figures la-b) .
Lymphocyte proliferation in low glucose concentrations Lymphocyte proliferation in 6mgdl ' and 32mgdl-l glucose concentrations was compared with proliferation in normal serum glucose concentration (125mgdl-'). Proliferation in 6mgdl-' glucose was significantly less than at 125mgdl-' Lymphocyte proliferation was significantly decreased in both conditions compared to room air (P <.0001 and P = 0049, respectively).
glucose (P = .01); proliferation was not significantly different between 32mgdl1' and 125mgdl1l glucose (Figure 2 ).
Lymphocyte proliferation in acidic pH
Lymphocyte proliferation in pH 7.0, 6.7, and 6.4 was compared to that at pH 7.4. Proliferation at pH 6.4 and 6.7 was significantly decreased, whereas proliferation was increased at pH 7.0 (P = .05 with Tukey's test) (Figure 3 ).
Discussion
The effectiveness of IL-2 therapy presumably depends upon a variety of factors, including toxicity, concentration of IL-2 delivered to the tumour, extent of lymphocytic infiltration, response of TIL to IL-2, and sensitivity of tumour cells to cytotoxic effects of the activated TIL. The present study examined IL-2-stimulated lymphocyte proliferation under the range of physico-chemical conditions reported for experimental tumours in laboratory animals. The actual tumour microenvironment is clearly more complex than this in vitro model, with other factors (including suppressor cells and soluble immunosuppressor factors) influencing TIL responsiveness as well. Splenic lymphocytes rather than TIL were employed in these experiments because the IL-2 receptor is not well expressed on TIL, and in vitro proliferative response of TIL to I1-2 is poor (Miescher et al., 1986 Glucose (mg dl-')
Figure 2 IL-2-stimulated lymphocyte proliferation in low glucose concentrations. Lymphocyte proliferation was significantly reduced in 6 mg dl-' glucose compared to 125 mg dl-' glucose (P = .01).
of more centrally located TIL may be down-regulated. However, tumour cells in hypoxic areas are more resistant to radiotherapy and some forms of chemotherapy than their well-oxygenated counterparts (Gray et al., 1953; Bush et al., 1978; Hill & Stanley, 1975; Tannock, 1982) (Rotin et al., 1986; Tannock & Kopelyan, 1986 (Fischer et al., 1986) , should be examined in animal models to determine if TIL response to IL-2 may be improved. The potential benefit of increasing TIL responsiveness by alteration of the tumour microenvironment must be evaluated against the possibility of concomitant increase in tumour cell proliferation under more normal physico-chemical conditions.
